Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605
Peter C. Black(University of British Columbia), Seth P. Lerner(Baylor College of Medicine), Wassim Kassouf(McGill University), Catherine M. Tangen(American Urological Association), Vadim S. Koshkin(UCSF Helen Diller Family Comprehensive Cancer Center), Melissa Plets(Cancer Research And Biostatistics), Sima P. Porten(City College of San Francisco), David J. McConkey(Johns Hopkins University), M. Scott Lucia(University of Colorado Anschutz Medical Campus), Kelly Stratton(Oklahoma City University), Parminder Singh(WinnMed), Trinity J. Bivalacqua(University of Pennsylvania), Rick Bangs(Bladder Cancer Advocacy Network), William T. Lowrance(University of Utah), Ian M. Thompson(The University of Texas at San Antonio Health Science Center)
Cited by 96
Related Papers
Frailty in Older Adults: Evidence for a Phenotype
|The Journals of Gerontology Series A|2001|24.4k
Neurohumoral Features of Myocardial Stunning Due to Sudden Emotional Stress
|New England Journal of Medicine|2005|3.1k
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
|New England Journal of Medicine|2003|2.6k